focus -WSS

focus

author：Wikipedia 2025-10-01 17:21:27 - browse：62588

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Congress considering partial increase for doctor pay in Medicare

leisure time

WSS

Biden’s NIH nominee is languishing in Congress

Latigo launches with $135 million for Vertex

The U.S. needs a new definition of substance use “recovery”

US sending controversial cluster munitions to Ukraine until other ammo is ready: Kirby

Recent heat wave in the Mediterranean caused by climate change: Study

Biden’s NIH nominee is languishing in Congress

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

What does generative AI mean for health care? We asked experts

Abbott's new heart device gets FDA advisory panel nod

After affirmative action ruling, medical educators look to 'holistic review'

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Eisai exec who led development of Alzheimer’s drug to retire

Peter Hotez and the public health issue of online harassment

Medicare wants to send $9 billion to 340B hospitals

Peter Hotez and the public health issue of online harassment

Parents surprise family after baby discharged from NICU after 170 days

focus

ACIP vaccine advisory panel sees its vacancies filled

Congress must protect the remaining independent doctors

US sending controversial cluster munitions to Ukraine until other ammo is ready: Kirby

ACA's risk program benefits Blue Cross Blue Shield insurers

Create a giant ice tray with this foil pan hack to keep food cold this summer

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

leisure time

focus

knowledge

focus